[Endothelin and kidney disease].
Nakayama
Yushi
Y
Department of Nephrology, Graduate School of Medical Sciences, Kumamoto University.
Tomita
Kimio
K
D000818:Animals; D016282:Aspartic Acid Endopeptidases / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D019898:Autocrine Communication; D002455:Cell Division; D016572:Cyclosporine / Q000009:adverse effects; D015195:Drug Design; D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1 / Q000235:genetics / Q000378:metabolism / Q000502:physiology*; D000072396:Endothelin-Converting Enzymes; D015870:Gene Expression; D005920:Glomerular Mesangium / Q000166:cytology / Q000378:metabolism; D006801:Humans; D007674:Kidney Diseases / Q000188:drug therapy* / Q000209:etiology*; D008666:Metalloendopeptidases; D063065:Organophosphonates / Q000627:therapeutic use; D013777:Tetrazoles / Q000627:therapeutic use; D014661:Vasoconstriction
D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1; D063065:Organophosphonates; D013777:Tetrazoles; C089987:CGS 26303; D016572:Cyclosporine; D016282:Aspartic Acid Endopeptidases; D008666:Metalloendopeptidases; D000072396:Endothelin-Converting Enzymes